All News
Measuring Disease Activity in PsA: Dr. Eric Ruderman
In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month.
Read Article
The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.
Read Article
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW https://t.co/x0iQ6XX3eJ
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict development of clinical RA in those at risk either w/ a
- +RF or +CCP
- Relevant sxs w/ or w/o abs
- 1st deg relatives do RA pts?
#ACR20 https://t.co/xVZHxL35UY
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Dr. John Cush RheumNow ( View Tweet)
New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20
https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
"RT @drdavidliew : This - very cool.
Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see!
#ACR20 ABST1995 @RheumNow https://t.co/cE3gQar0zo https://t.co/bmGnrMGaq3
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate.
https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Links:
Dr. John Cush RheumNow ( View Tweet)
Revisit our #ACR20 coverage. Listen to our Day 3 recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/IbfY5vbBAo https://t.co/YL9fAuO0oz
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group
Dr. John Cush RheumNow ( View Tweet)
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
Disease flare 19% in tx vs. 46% in PBO at 26wk
Sustained remission 83% vs. 50% in PBO
Similar AE in both groups Abs#L06
https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX
Links:
Dr. John Cush RheumNow ( View Tweet)
Listen to our latest QD podcast on differential Dx of Arthritis in HIV+ individuals, possibilities with hyperuricemia in Psoriatic Arthritis MDA5 myositis reviewed, difficult RA with serious infections and limited options.
https://t.co/HGjgkMmOzp https://t.co/jFs8kINS3U
Links:
Dr. John Cush RheumNow ( View Tweet)
New ACR RA Guidelines and Practice Changing Abstracts #ACR20
https://t.co/3lGSUDks8F
Links:
Dr. John Cush RheumNow ( View Tweet)
Listen now! Dr. Jack Cush leads a panel of experts regarding Still's Disease and #ACR20. Download our podcasts on Apple and Android devices.
https://t.co/eV5jR0BIXO https://t.co/IChHpeiI9x
Links:
Dr. John Cush RheumNow ( View Tweet)
Listen as Dr. Petryna ( @DrPetryna) reviews several pegloticase-related abstracts presented at the #ACR20 meeting.
https://t.co/TBi1uRPXG0 https://t.co/wAUNr4mq1v
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @bella_mehta : VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/IEC8IfE0LC https://t.co/jV3EYK0NUK
Links:
Dr. John Cush RheumNow ( View Tweet)
Long-Term Prognosis in Children with Kawasaki Disease: Dr. David Liew ( @drdavidliew) #ACR20
https://t.co/Hg8nYWcD3V https://t.co/pJIGNMnRss
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. https://t.co/GCZj64i86c https://t.co/Pd6qGEGOev
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MGHrheumatology : Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/wvKvCDO1m4 https://t.co/wCGG2lIqAr
Links:
Dr. John Cush RheumNow ( View Tweet)
